methylphenidate patch Daytrana
Selected indexed studies
- Stimulants. (Child Adolesc Psychiatr Clin N Am, 2022) [PMID:35697391]
- Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. (Expert Rev Clin Pharmacol, 2023) [PMID:37587841]
- Prescription of Controlled Substances: Benefits and Risks. (, 2026) [PMID:30726003]
_Worker-drafted node — pending editorial review._
Connections
methylphenidate patch Daytrana is a side effect of
Sources
- Prescription of Controlled Substances: Benefits and Risks. (2026) pubmed
- Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. (2023) pubmed
- Stimulants. (2022) pubmed
- Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). (2014) pubmed
- MethyPatch Noven. (2002) pubmed
- Drugs for ADHD. (2015) pubmed
- Methylphenidate patch-test protocol and irritancy threshold determination in healthy adult subjects. (2009) pubmed
- Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery. (2011) pubmed
- Evaluating elevated release liner adhesion of a transdermal drug delivery system (TDDS): a study of Daytrana™ methylphenidate transdermal system. (2011) pubmed
- Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats. (2014) pubmed